Last reviewed 2026-04-22 · How we verify

BCD-085 Q2W

BCD-085 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.

BCD-085 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).

At a glance

Mechanism of action

BCD-085 is a fully human monoclonal antibody targeting programmed death ligand 1 (PD-L1) on tumor cells and immune cells. By blocking the PD-L1/PD-1 axis, it prevents the suppression of T-cell mediated anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells. The Q2W dosing indicates biweekly administration.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation)

Common side effects

• Fatigue
• Infusion-related reactions
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Decreased hemoglobin

Key clinical trials

• An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.